StockData
Lexicon Pharmaceuticals, Inc. logo

Lexicon Pharmaceuticals, Inc. (LXRX) stock

LXRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 5/3087% above fair value
$1.72−0.06 (-3.37%)

Close on Nov 18, 2026Market cap $765.32MP/E –Yield –

Lexicon Pharmaceuticals pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

Lexicon Pharmaceuticals's pe ratio was 13.6× on Oct 29, 2021, against 2.3× a year earlier.

PE Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2021Oct 29, 202113.6×+7.7
2020Oct 30, 20205.8×+2.8
2019Dec 31, 20193.1×–

More Lexicon Pharmaceuticals figures

See a number that looks wrong?